Search Results - "Overdijk MB"

Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis.

Authors: Akanksha Bouzeyen, Rania Watson, Avia et al.

Source: PLoS Pathogens. 5/27/2026, Vol. 22 Issue 5, p1-16. 16p.

Exploring the impact of antibody-dependent cellular phagocytosis-related genes on the prognosis of metastatic melanoma.

Authors: Chen, Junhao He, Jiapeng Xu, Xiaolong et al.

Source: PLoS ONE. 10/9/2025, Vol. 20 Issue 10, p1-22. 22p.

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Authors: Bahlis, Nizar J. Zonder, Jeffrey Karlin, Lionel et al.

Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 14, p2685-2696. 12p.

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study.

Authors: Yang W Wang L Wang Y et al.

Source: Annals of hematology [Ann Hematol] 2026 Apr 13; Vol. 105 (5). Date of Electronic Publication: 2026 Apr 13.

Publication Type: Journal Article; Multicenter Study; Observational Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade.

Authors: Altıntaş, Işıl Nürmberger, Kristina B. Imle, Andrea et al.

Source: Scientific Reports. 7/24/2025, Vol. 15 Issue 1, p1-15. 15p.

Author Index.

Source: European Journal of Clinical Investigation. May2014 Supplement, Vol. 44, p87-91. 5p.

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

Authors: Xia, Zhongjun Leng, Yun Fang, Baijun et al.

Source: BMC Cancer. 10/14/2023, Vol. 23 Issue 1, p1-14. 14p.

High-throughput single-cell analysis reveals fully human Omp38-specific monoclonal antibodies against Acinetobacter baumannii.

Authors: Zhang, Yiwei Yu, Wenkang Yu, Peng et al.

Source: BMC Microbiology. 8/20/2025, p1-17. 17p.

Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives.

Authors: Gu Q Li S Hou S et al.

Source: Journal of translational medicine [J Transl Med] 2026 Mar 19; Vol. 24 (1). Date of Electronic Publication: 2026 Mar 19.

Publication Type: Journal Article; Review

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE

Light-chain-restricted hematogones are a potential diagnostic pitfall for B-cell lymphoma.

Authors: Yang, Xiaofeng Zhang, Zhihua Yang, Xinhong

Source: Indian Journal of Pathology & Microbiology. Oct-Dec2025, Vol. 68 Issue 4, p766-768. 3p.

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis.

Authors: Huang, Xiaohua Zhou, Jia Qian, Yuxiao et al.

Source: Systematic Reviews. 5/16/2025, Vol. 14 Issue 1, p1-13. 13p.

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.

Authors: Wang, Luqun Yang, Wei Wang, Yafei et al.

Source: BMC Cancer. 5/7/2025, Vol. 25 Issue 1, p1-16. 16p.

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis.

Authors: Jiang, Hua Li, Lu Guo, Meiyu et al.

Source: Hematology. Dec2024, Vol. 29 Issue 1, p1-13. 13p.

Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.

Authors: Eleutherakis Papaiakovou, Evangelos Terpos, Evangelos Kanellias, Nikolaos et al.

Source: Leukemia & Lymphoma. Dec2023, Vol. 64 Issue 13, p2140-2147. 8p.

Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.

Authors: Antonioli, Elisabetta Staderini, Michela Pilerci, Sofia et al.

Source: Leukemia & Lymphoma. Dec2020, Vol. 61 Issue 13, p3255-3258. 4p.

Targeting programmed cell death: a novel therapeutic paradigm for cancer based on mode-of-death classification.

Authors: Qiao X Ye T Wu T et al.

Source: Apoptosis : an international journal on programmed cell death [Apoptosis] 2026 Jun 08; Vol. 31 (6). Date of Electronic Publication: 2026 Jun 08.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 9712129 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-675X (Electronic) Linking ISSN: 13608185 NLM ISO Abbreviation: Apoptosis Subsets: MEDLINE

Revelation of prognosis and tumor microenvironment of colorectal cancer based on genes related to antibody-dependent cellular phagocytosis and single-cell landscape.

Authors: Yang, Leilei Han, Jiaju Ma, Weiwei et al.

Source: Clinical Proteomics. 8/21/2025, Vol. 22 Issue 1, p1-17. 17p.

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review.

Authors: Tauseef, Abubakar Zafar, Maryam Silberstein, Peter et al.

Source: Journal of Family Medicine & Primary Care. Jun2022, Vol. 11 Issue 6, p2648-2655. 8p.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Authors: Bahlis, Nizar J. Siegel, David S. Schiller, Gary J. et al.

Source: Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1407-1417. 11p.

Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma.

Authors: Abdallah, Al‐Ola Mahmoudjafari, Zahra Ahmed, Nausheen et al.

Source: European Journal of Haematology. Jun2023, Vol. 110 Issue 6, p626-632. 7p.